Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

83.41
-0.7700-0.91%
Post-market: 82.15-1.2600-1.51%16:39 EDT
Volume:919.72K
Turnover:77.48M
Market Cap:5.33B
PE:-78.15
High:85.41
Open:84.50
Low:83.27
Close:84.18
Loading ...

BUZZ-Leerink Partners raises PT on Blueprint Medicines

Reuters
·
15 Jan

Cautious Hold Rating for Third Harmonic Bio Amid Competitive Pressure from Blueprint Medicines

TIPRANKS
·
15 Jan

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

Zacks
·
14 Jan

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Zacks
·
14 Jan

Blueprint Medicines Corp : Leerink Partners Raises Target Price to $98 From $89

THOMSON REUTERS
·
14 Jan

Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?

Zacks
·
14 Jan

Blueprint Medicines Shares Jump on View That Ayvakit Could Hit $2B in Revenue by 2030

Dow Jones
·
14 Jan

Blueprint Medicines Highlights 2024 Achievements and Future Growth

TIPRANKS
·
14 Jan

Blueprint Medicines Expects Systemic Mastocytosis Franchise to Generate $4 Billion by 2030 -- Shares Up

MT Newswires Live
·
14 Jan

Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor

GuruFocus.com
·
14 Jan

Blueprint Medicines: Promising Pipeline and Financial Strength Justify Buy Rating

TIPRANKS
·
13 Jan

Blueprint Medicines Corp : Wedbush Cuts Target Price to $124 From $135

THOMSON REUTERS
·
13 Jan

Blueprint Medicines Price Target Maintained With a $135.00/Share by Needham

Dow Jones
·
13 Jan

Blueprint Medicines: Aggressive Growth Trajectory and Promising Future Drivers Justify Buy Rating

TIPRANKS
·
13 Jan

Blueprint Medicines: Balancing Promising Developments with Cautious Hold Rating Amid Competitive Landscape

TIPRANKS
·
13 Jan

Blueprint Medicines: Promising Growth with Increased Sales Projections and Innovative Pipeline Supports Buy Rating

TIPRANKS
·
13 Jan

BRIEF-Blueprint Medicines Says Expect To Achieve $2 Billion In Ayvakit Revenue By 2030

Reuters
·
13 Jan

Blueprint Medicines Corp - Expect to Achieve $2 Bln in Ayvakit Revenue by 2030

THOMSON REUTERS
·
13 Jan

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

THOMSON REUTERS
·
13 Jan

Barclays Reaffirms Their Hold Rating on Blueprint Medicines (BPMC)

TIPRANKS
·
09 Jan